‘Biosimilar’ Drugs for Rheumatoid Arthritis Actually Cost Patients More
The availability of biosimilars commonly used to treat moderate to severe RA may not by itself reduce out-of-pocket costs for Medicare beneficiaries due to a lack of manufacturer discounts.
![](/sites/default/files/styles/news_card__image/public/fields/field_insert_file/news/pills.jpg)